Bone and Mineral Metabolism Disorders News

WASHINGTON — Use of the sucroferric oxyhydroxide binder by Fresenius Medical Care Renal Therapies Group, Velphoro, was effective in lowering serum phosphorus levels for patients in their first year of hemodialysis therapy, according to results presented here.

WASHINGTON — Patiromer was effective in controlling serum potassium in hyperkalemic patients with diabetes and advanced kidney disease on renin-angiotensin-aldosterone system inhibitors, according to research presented here.

WASHINGTON — For patients on hemodialysis who eat rice as a main source of calories, low-protein rice plus low-phosphorus whey can reduce serum phosphorus and improve serum albumin, according to study results presented at ASN Kidney Week.

Researchers of a published study found patients on hemodialysis who had secondary hyperparathyroidism were able to detect a worsening of symptoms related to increases in parathyroid hormone levels.

PHILADELPHIA — Concomitant use of the potassium binder patiromer enabled more patients with resistant hypertension and advanced chronic kidney disease to continue treatment with spironolactone, with less hyperkalemia, according to new data from the AMBER trial presented at the Heart Failure Society of America Scientific Meeting.

Researchers found differences for levels of parathyroid hormone, calcium and phosphorus in the first 5 years of hemodialysis based on patient race and country of origin.

Managing the cascade of illness triggered by the imbalance of calcium and phosphorus challenges physicians who care for patients with CKD.

Solid organ transplant recipients who develop hyperkalemia have an increased risk of mortality and 30-day readmissions, according to results presented at ASN Kidney Week 2018.

A recently published study shows use of patiromer in a large, hemodialysis patient population proved effective in reducing hyperkalemia.

SAN DIEGO — In this exclusive video from ASN Kidney Week 2018, Ian Sabir, June Zhao, MD, PhD and Ayman Al-Shurbaji, MD, PhD, discuss a phase III study that compared 5 g and 10 g of Lokelma (sodium zirconium cyclosilicate, AstraZeneca) with placebo for the treatment of hyperkalemia.